A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas

The University of Texas Health Science Center, Houston254 enrolled

Overview

Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved in 2007. It is currently one of the preferred treatment regimens for HIV by the Department of Health and Human Services. It has become a widely used antiretroviral therapy option for HIV infected patients. It provides good tolerability and a favorable lipid profile for patients when compared to some other antiretroviral treatment options. Little data is reported about efficacy in a minority patient population. Moreover, data in an indigent minority population in the United States has not been aggregated before. Therefore this study will investigate the efficacy of raltegravir in minority women residing in Houston, TX who are HIV infected.

Study Type

OBSERVATIONAL

Enrollment

254

Conditions

HIV Infection

Interventions

raltegravirDRUG

HIV therapy component

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: 1. HIV-infected women who picked up raltegravir in the year 2013 at Thomas Street Health Center. 2. Minority women -Black/African American, Hispanic/Latino Exclusion Criteria: * n/a

Locations (1)

Thomas Street Clinic

Houston, Texas, United States

Outcomes

Primary Outcomes

Assess the efficacy of raltegravir in study participants by measuring CD4 count and viral load

Time frame: 24 weeks of therapy

Secondary Outcomes

Capture data on concomitant conditions that may have led to participants switching to raltegravir from medical records (eg. Diabetes mellitus)

Time frame: 24 weeks of therapy

Assess tolerability of raltegravir by capturing symptoms

Time frame: 24 weeks of therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.